Researchers develop ‘armored’ CAR-T with potential against solid tumors
Mouse model study uses PD-1 antibody technology from Eureka Therapeutics, which is also developing T-cell receptor therapies.
GP Capital
Mouse model study uses PD-1 antibody technology from Eureka Therapeutics, which is also developing T-cell receptor therapies.